2. Endocrinology

Endocrinology

Endocrinology

Related Products

PDF 21.44 MB

Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS).

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-125836
    CCR4 antagonist 2 2206788-99-8 98%
    CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.
    CCR4 antagonist 2
  • HY-125839
    OP-3633 2102494-14-2 98%
    OP-3633 is a potent and selective steroidal glucocorticoid receptor (GR) antagonist with an IC50 of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism.
    OP-3633
  • HY-13106A
    Olodanrigan sodium 1316755-17-5 98%
    Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
    Olodanrigan sodium
  • HY-13209C
    Ambrisentan sodium 1386915-48-5 98%
    Ambrisentan (BSF 208075) sodium is a selective and orally active ET type A receptor (ETAR) antagonist.
    Ambrisentan sodium
  • HY-13627A
    Estramustine phosphate 4891-15-0 98%
    Estramustine phosphate, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer.
    Estramustine phosphate
  • HY-14289A
    Cimetidine hydrochloride 70059-30-2 98%
    Cimetidine (SKF-92334) hydrochloride is an orally active and inverse histamine H2 receptor antagonist with a Ki of 0.6 μM. Cimetidine hydrochloride is a gastric acid reducer, and can be used for duodenal and gastric ulcers research. Cimetidine hydrochloride has anti-cancer and anti-inflammatory activity.
    Cimetidine hydrochloride
  • HY-151198
    CHF-6366 1615208-41-7 98%
    CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD).
    CHF-6366
  • HY-152856
    Merigolix 1454272-94-6 98%
    Merigolix is a potent gonadotrophin releasing hormone (GnRH) antagonist.
    Merigolix
  • HY-153113
    Rongliflozin 2648020-91-9 98%
    Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).
    Rongliflozin
  • HY-153219
    P-CAB agent 2 hydrochloride 2209911-80-6 98.0%
    P-CAB agent 2 hydrochloride is a potent and orally active potassium-competitive acid blocker and a gastric acid secretion inhibitor. P-CAB agent 2 hydrochloride inhibits H+/K+-ATPase activity with an IC50 value of <100 nM. P-CAB agent 2 hydrochloride inhibits the hERG potassium channel with an IC50 value of 18.69 M. P-CAB agent 2 hydrochloride shows no acute toxicity and inhibits histamine (HY-B1204)-induced gastric acid secretion.
    P-CAB agent 2 hydrochloride
  • HY-15746B
    Dobutamine tartrate 101626-66-8 98%
    Dobutamine tartrate is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine tartrate is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine tartrate can increase cardiac output and correct hypoperfusion.
    Dobutamine tartrate
  • HY-16168B
    Degarelix acetate hydrate 934246-14-7 98%
    Degarelix acetate hydrate (FE 200486 acetate hydrate) is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research.
    Degarelix acetate hydrate
  • HY-17021C
    Esomeprazole hemistrontium 914613-86-8 98%
    Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole hemistrontium
  • HY-18252A
    Avanafil dibenzenesulfonate 330784-48-0 98%
    Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil dibenzenesulfonate
  • HY-A0261A
    Pentagastrin meglumine 57448-84-7 98%
    Pentagastrin (ICI-50123) meglumine is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin meglumine enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury..
    Pentagastrin meglumine
  • HY-B0256A
    Azathioprine sodium 55774-33-9 98%
    Azathioprine (BW 57-322) sodium is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis.
    Azathioprine sodium
  • HY-B0442C
    Vardenafil dihydrochloride 224789-15-5 98%
    Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes-.
    Vardenafil dihydrochloride
  • HY-B1232A
    Metyrapone Tartrate 908-35-0 98%
    Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression.
    Metyrapone Tartrate
  • HY-P1959B
    Lanreotide diTFA 1024499-83-9 98%
    Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome.
    Lanreotide diTFA
  • HY-100007A
    Vonoprazan hydrochloride 1957202-44-6 98%
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori.
    Vonoprazan hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity